Actelion CEO Says 120 Patients Died in Lung Drug Study

Actelion Ltd., the Swiss drugmaker, said 120 people died in a clinical trial of more than 700 patients involving its experimental medicine macitentan.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.